Future Healthcare 100: A Decade of Innovation, 4,464 Companies Recognized, Over 100 IPOs — The Definitive Benchmark for Medical Innovation Value
To Every Innovator in the Healthcare Industry:
Hope this letter finds you well!
A Decade Fleets By; The Land Embraces Renewal.
Over the past decade, China’s healthcare industry has achieved a leap from following to keeping pace, from importing to originating, and from isolated breakthroughs to ecosystem-wide synergy. Chinese-made innovative drugs have repeatedly achieved remarkable success in overseas licensing deals, high-end medical devices have broken multinational monopolies, and frontier technologies such as digital therapeutics, cell and gene therapy, and brain science have moved from the laboratory to clinical practice. Each step bears testament to the dedication and innovation of industry professionals.
Growing alongside this vibrant hub of innovation is the VCBeat Future Healthcare 100 List.
Since the release of the first ranking in 2016,To date, we have launched 277 ranking awards and published six industry growth analysis reports, witnessing 4,464 healthcare companies take the stage, while honoring 1,237 industry-enabling institutions and ecosystem partners, as well as 489 industry leaders.
These strings of figures are not cold records, but rather a testament to the mutual reinforcement and co-evolution of the rankings and the industry.
In 2026, the Top 100 Future Healthcare Companies selection marks its 10th anniversary. In response to the industry’s urgent need for value discovery, validation, and amplification of healthcare innovation assets, we firmly believe that the significance of this list extends far beyond merely documenting industrial milestones or providing industry rankings; rather, it lies in foreseeing the future of innovation and deeply empowering growth.
To this end, the selection process will employ more precise metrics to anchor the true value of medical innovation, while adopting a more comprehensive perspective to conduct a panoramic scan of the core forces driving medical innovation.
We have returned the rankings to their core focus on growth, precisely targeting every active innovator: For the first time, the ranking of non-listed companies has unified the eligibility criteria.Required atCompleted at least one round of financing after January 1, 2023, or can provide supporting documentation for valuation., identifying high-quality enterprises in their accelerated growth phase,Valuation data for the three major main charts will be fully disclosed., enabling companies with strong core competencies to gain commensurate industry reputation.
For listed companies, we have established a dual-axis evaluation framework of “Innovation + Global Expansion.”Added: Global Expansion Strength Ranking, mapping out a comprehensive profile of corporate strength through internal capabilities and global competitiveness, in response to the inevitable demand for industries to go global.
We Empower Awards Through Synergy, Capturing Every Force That Supports Industry Growth: SelectionBreaking Down Sector and Role Boundaries: Bringing Scientists, Entrepreneurs, and Investors to the Same Stage, and Aligning Capital, Services, and Platforms。
Five Award Categories Redefining Industry Value: From innovative individuals driving collaborative impact, to institutions equally recognizing the value of capital and professional services; from ecosystem trends that uncover diverse values, to high-quality enterprises covering the entire lifecycle, and finally to innovative products and technologies anchored in “China’s First Launches and Pioneering Innovations.” We aim to ensure that every force propelling industry progress is precisely identified and fully recognized.
After a decade of dedication, we understand that the true value of a ranking lies not in the list itself, but in the growth trajectories of the companies featured. As of 2026, we have witnessedOver 100 Listed Companies Complete Their Transformation from Startup to IPO。
But we are even more aware that a company’s development extends far beyond its IPO. True growth potential lies in the ability to survive across industry cycles, to effectively translate technology into products and revenue, and to expand from local markets to the global stage and from single-product offerings to a diversified portfolio. From 2023 to 2025,190+ Companies Listed for Three Consecutive Years, they are building barriers, conducting validations, and establishing thought leadership in their respective sectors—serving as the most vivid testament to this growth potential.
This precise identification of high-quality enterprises stems from our unwavering commitment to “innovation” over the past decade. In 2015, as the wave of healthcare venture capital investment began to rise and pharmaceutical regulatory reforms were unveiled, we conceived this list: rejecting simple rankings by scale and abandoning traditional industry awards, we focus solely on “innovation” to discover the emerging forces that represent the future.
After years of iterative refinement, the ranking has evolved from a single main list into a comprehensive evaluation system that covers the entire corporate lifecycle and encompasses all core stakeholders in the industry. Each iteration serves as a precise response to industrial transformation, while every adjustment represents a deep alignment with industry needs.
Standing at the new starting point of a decade, we have distilled this steadfast commitment into“Exhibition, Trading, and Empowerment of Innovative Chinese Medical Assets”'s core positioning.
We areThe "Magnifying Glass" of Innovative Value, enabling companies to gain concentrated attention from capital markets, industries, and government, thereby achieving precise value discovery; we are“Connector” of Industrial Resources, leveraging conferences, closed-door roadshows, and industry matchmaking sessions to enable companies to directly access unmet clinical needs and potential partners, facilitating efficient connections; we further“Companion” for Corporate Growth, through annual data reviews and milestone reports, to help companies anchor themselves at cyclical nodes and calibrate their growth trajectory.
It is our unwavering pursuit to transform the ranking from a static list of honors into a dynamic, continuous companion in value creation.
We have been privileged to walk alongside China’s healthcare industry through a sweeping journey of innovation. Looking ahead, the golden age of Chinese medical innovation has only just begun: continuous vitality in innovative asset transactions, accelerating inflows of global capital, and the mass emergence of “first-in-China” breakthroughs are converging and resonating, propelling China’s medical innovation into an entirely new ecological niche.
The Future Healthcare Top 100 selection will continue to use the ranking as a value benchmark, awards as a bridge for collaboration, and the ecosystem as fertile ground for growth. It aims to accompany more innovative enterprises in navigating industry cycles and expanding globally. With a holistic, end-to-end platform perspective, it seeks to convey the true value of medical innovation and empower every innovative force to move faster, farther, and more steadily.
We have always believed that what truly defines the future is never the awards themselves, but rather the enterprises and pioneers who silently transform the healthcare industry through technology, products, and conviction. All we can do is to be present, to witness, and to walk alongside them as these changes unfold.
A Decade of New Journeys, Unwavering Commitment. The 2026 Future Healthcare Top 100 Selection marks its 10th edition. We invite you to join us as we embark on the next decade of healthcare innovation and collectively paint a new vision for industry development!
VCBeat · Top 100 Future Healthcare Companies Selection Committee
March 1, 2026
